Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling

被引:110
作者
Elpek, Kutlu G.
Yolcu, Esma S.
Franke, Deanna D. H.
Lacelle, Chantale
Schabowsky, Rich-Henry
Shirwan, Haval
机构
[1] Univ Louisville, Inst Cellular Therapeut, Louisville, KY 40202 USA
[2] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA
关键词
D O I
10.4049/jimmunol.179.11.7295
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Naturally occurring CD4(+)CD25(+)FoxP3(+) T regulatory (Treg) cells require three distinct signals transduced via TCR, CD28, and IL-2R for their development and maintenance. These requirements served as the basis for several recently developed ex vivo expansion protocols that relied on the use of solid support-bound Abs to CD3 and CD28 in the presence of high dose IL-2. We report in this study that Treg cells up-regulate the expression of inducible costimulatory receptor 4-1BB in response to IL-2, and stimulation using this receptor via a novel form of 4-1BB ligand (4-1BBL) fused to a modified form of core streptavidin (SA-4-1BBL) was effective in expanding these cells up to 110-fold within 3 wk. Expanded cells up-regulated CD25, 4-1BB, and membranous TGF-beta, suppressed T cell proliferation, and prevented the rejection of allogeneic islets upon adoptive transfer into graft recipients. Importantly, SA-4-1BBL rendered CD4(+)CD25(-) T effector cells refractive to suppression by Treg cells. This dual function of signaling via 4-1BB, vis-A-vis Treg cell expansion and licensing T effector cells resistant to Treg cell suppression, as well as the up-regulation of 4-1BB by IL-2 may serve as important regulatory mechanisms for immune homeostasis following antigenic challenge. Stimulation using a soluble form of SA-4-1BBL represents a novel approach to expand Treg cells with potential therapeutic applications in autoimmunity and transplantation.
引用
收藏
页码:7295 / 7304
页数:10
相关论文
共 62 条
[1]   An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation [J].
Asseman, C ;
Mauze, S ;
Leach, MW ;
Coffman, RL ;
Powrie, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (07) :995-1003
[2]  
Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO
[3]  
2-S
[4]   Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells [J].
Barao, I ;
Hanash, AM ;
Hallett, W ;
Welniak, LA ;
Sun, K ;
Redelman, D ;
Blazar, BR ;
Levy, RB ;
Murphy, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (14) :5460-5465
[5]   CD25+CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production [J].
Barthlott, T ;
Moncrieffe, H ;
Veldhoen, M ;
Atkins, CJ ;
Christensen, J ;
O'Garra, A ;
Stockinger, B .
INTERNATIONAL IMMUNOLOGY, 2005, 17 (03) :279-288
[6]   Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].
Battaglia, M ;
Stabilini, A ;
Roncarolo, MG .
BLOOD, 2005, 105 (12) :4743-4748
[7]   The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].
Bennett, CL ;
Christie, J ;
Ramsdell, F ;
Brunkow, ME ;
Ferguson, PJ ;
Whitesell, L ;
Kelly, TE ;
Saulsbury, FT ;
Chance, PF ;
Ochs, HD .
NATURE GENETICS, 2001, 27 (01) :20-21
[8]  
Boden Elisa, 2003, Novartis Found Symp, V252, P55
[9]   Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse [J].
Brunkow, ME ;
Jeffery, EW ;
Hjerrild, KA ;
Paeper, B ;
Clark, LB ;
Yasayko, SA ;
Wilkinson, JE ;
Galas, D ;
Ziegler, SF ;
Ramsdell, F .
NATURE GENETICS, 2001, 27 (01) :68-73
[10]   A new carboxamide compound exerts immunosuppressive activity by inhibiting dendritic cell maturation [J].
Carbonnelle, D ;
Ebstein, F ;
Rabu, C ;
Petit, JY ;
Gregoire, M ;
Lang, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (02) :546-556